Hanauer S B
Dept. of Medicine, University of Chicago Medical Center, Illinois 60637.
Scand J Gastroenterol Suppl. 1990;172:56-9. doi: 10.3109/00365529009091912.
Sulfasalazine continues to be a common treatment for active Crohn's disease. It has been shown to be more effective than placebo in patients with colonic disease and in patients without prior surgical resection. There is no clear clinical evidence for its use as maintenance therapy in quiescent Crohn's disease; nevertheless, it is widely used to prevent symptom recurrence in patients whose active disease responded to sulfasalazine. In a few preliminary controlled studies, mesalazine has been shown to be superior to placebo in the treatment of active Crohn's disease. Until recently, the results of trials of mesalazine as maintenance therapy in quiescent Crohn's disease were equivocal but promising.
柳氮磺胺吡啶仍然是活动性克罗恩病的常用治疗药物。在患有结肠疾病的患者以及未接受过手术切除的患者中，它已被证明比安慰剂更有效。目前尚无明确的临床证据表明其可用于静止期克罗恩病的维持治疗；尽管如此，它仍被广泛用于预防对柳氮磺胺吡啶有反应的活动性疾病患者的症状复发。在一些初步对照研究中，美沙拉嗪已被证明在治疗活动性克罗恩病方面优于安慰剂。直到最近，关于美沙拉嗪作为静止期克罗恩病维持治疗的试验结果尚无定论，但前景乐观。
